Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WX390 in advanced solid tumors with PIK3CA mutations
NCT06132932Phase 2Completed
- Sponsor
- Shanghai Jiatan Pharmatech
- Start
- Jun 2021
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of WXFL10030390 in solid tumor (advanced stage), sponsored by Shanghai Jiatan Pharmatech. Primary endpoints: Safety of WX390 at 24 weeks and Objective Response Rate at 24 weeks. Started Jun 2021; status: completed.
02
Drugs
WXFL10030390
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06132932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06132932.